Skip to Content
Merck

PZ0012

Sunitinib malate

≥98% (HPLC), powder, receptor tyrosine kinase inhibitor

Synonym(s):

N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-2-hydroxybutanedioic acid (1:1) salt, SU 011248, SU 11248, SU112248

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C22H27FN4O2 · C4H6O5
CAS Number:
341031-54-7
Molecular Weight:
532.56
UNSPSC Code:
12352200
PubChem Substance ID:
329823681
NACRES:
NA.77
MDL number:
MFCD08282795

Product Name

Sunitinib malate, ≥98% (HPLC)

SMILES string

O[C@@H](CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C

InChI key

LBWFXVZLPYTWQI-IPOVEDGCSA-N

InChI

1S/C22H27FN4O2.C4H6O5/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28;5-2(4(8)9)1-3(6)7/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28);2,5H,1H2,(H,6,7)(H,8,9)/b17-12-;/t;2-/m.0/s1

assay

≥98% (HPLC)

form

powder

solubility

DMSO: >10 mg/mL

storage temp.

room temp

Quality Level

100

Gene Information

human ... CSF1R(1436), FLT1(2321), FLT3(2322), FLT4(2324), KDR(3791), KIT(3815), PDGFRA(5156), PDGFRB(5159), RET(5979)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Sunitinib malate has been used:
  • to study its mechanism in the inhibition of MCF-7 cell migration and angiogenesis
  • as a reference molecule to compare its docking energies with other ligands/vascular endothelial growth factor receptor (VEGF) receptor blocker
  • used in proliferation assay

Biochem/physiol Actions

Sunitinib has greater bioavailability and potency compared to other inhibitors. It prevents angiogenesis.
Sunitinib malate is a receptor tyrosine kinase inhibitor, which targets VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, FLT3, CSF-1R, and RET. Sunitinib malate is an anticancer drug.

Features and Benefits

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H360,H372

Hazard Classifications

Repr. 1B - STOT RE 1 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000338683
0000338683
030M4706V
0000058519
030M47063

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sunitinib: from rational design to clinical efficacy
Chow LQM and Eckhardt SG
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(7), 884-896 (2007)
Iris Uribesalgo et al.
EMBO molecular medicine, 11(8), e9266-e9266 (2019-07-04)
Angiogenesis is a hallmark of cancer, promoting growth and metastasis. Anti-angiogenic treatment has limited efficacy due to therapy-induced blood vessel alterations, often followed by local hypoxia, tumor adaptation, progression, and metastasis. It is therefore paramount to overcome therapy-induced resistance. We
Nils Ohnesorge et al.
Frontiers in pharmacology, 10, 508-508 (2019-06-11)
Unbiased screening of large randomized chemical libraries in vivo is a powerful tool to find new drugs and targets. However, forward chemical screens in zebrafish can be time consuming and usually >99% of test compounds have no significant effect on
Suma Choorapoikayil et al.
Disease models & mechanisms, 6(5), 1159-1166 (2013-05-31)
Angiogenesis, the emergence of vessels from an existing vascular network, is pathologically associated with tumor progression and is of great interest for therapeutic intervention. PTEN is a frequently mutated tumor suppressor and has been linked to the progression of many
In-silico screening and In-vitro validation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) inhibitors
Saraswat D, et al.
Bioinformation, 10(5), 273-273 (2014)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service